ArticleProceedings of the National Academy of Sciences of the United States of America2021
The small molecule Zaractin activates ZAR1-mediated immunity in
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Decursin, Identified via High-Throughput Chemical Screening, Enhances Plant Disease Resistance via Two Independent Mechanisms.Molecular plant pathology · 2025Article
- Metformin blocks BIK1-mediated CPK28 phosphorylation and enhances plant immunity.Journal of advanced research · 2025Article
- Membrane vesicle engineering with "à la carte" bacterial-immunogenic molecules for organism-free plant vaccination.Microbial biotechnology · 2023Review
- The clubroot pathogen Plasmodiophora brassicae: A profile update.Molecular plant pathology · 2023Review
- The Arabidopsis effector-triggered immunity landscape is conserved in oilseed crops.Scientific reports · 2022Article
- ZAR1: Guardian of plant kinases.Frontiers in plant science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic effector proteins use a variety of enzymatic activities to manipulate host cellular proteins and favor the infection process. However, these perturbations can be sensed by nucleotide-binding leucine-rich-repeat (NLR) proteins to activate effector-triggered immunity (ETI). Here we have identified a small molecule (Zaractin) that mimics the immune eliciting activity of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.